Key Colorectal Cancer Therapeutics Market Players:
- Roche
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Merck & Co.
- Bristol-Myers Squibb
- Amgen
- Pfizer
- Novartis
- Sanofi
- AstraZeneca
- Eli Lilly
- Bayer
- Johnson & Johnson
- GSK (GlaxoSmithKline)
- Celltrion
- Biocon
- Takeda Pharmaceutical
- Daiichi Sankyo
- Astellas Pharma
- Otsuka Pharmaceutical
- Eisai Co.
- Chugai Pharmaceutical
The market hosts an intensifying landscape with giants such as Roche, Merck, and Bristol-Myers Squibb dominating with the presence of immunotherapies and targeted drugs. Besides the U.S. and Europe-based players lead in terms of checkpoint inhibitors, whereas emerging economies such as India and South Korea contribute biosimilars at an affordable cost. Further, the strategic collaborations opted for by Chugai and Roche shape innovation in this sector.
Here is the list of some prominent players in the industry:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of the colorectal cancer therapeutics market was over USD 14.2 billion.
The market size for the colorectal cancer therapeutics market is projected to reach USD 21.7 billion by the end of 2035, expanding at a CAGR of 4.8% during the forecast period, i.e., between 2026-2035.
The major players in the market are Roche, Merck & Co., Bristol-Myers Squibb, Amgen, and others.
In terms of the cancer stage segment, the metacystic stage segment is anticipated to garner the largest market share of 4.8%% by 2035 and display lucrative growth opportunities during 2026-2035.
The market in North America is projected to hold the largest market share of 42.7% by the end of 2035 and provide more business opportunities in the future.
